Invention Grant
- Patent Title: Fused tricyclic imidazo pyrazines as modulators of TNF activity
-
Application No.: US15580137Application Date: 2016-06-07
-
Publication No.: US10472362B2Publication Date: 2019-11-12
- Inventor: Victoria Elizabeth Jackson , Jag Paul Heer , Uwe Heinelt
- Applicant: UCB Biopharma SPRL
- Applicant Address: BE Brussels
- Assignee: UCB BIOPHARMA SPRL
- Current Assignee: UCB BIOPHARMA SPRL
- Current Assignee Address: BE Brussels
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- Priority: GB1509888.2 20150608
- International Application: PCT/EP2016/062898 WO 20160607
- International Announcement: WO2016/198398 WO 20161215
- Main IPC: C07D487/04
- IPC: C07D487/04 ; C07D491/147 ; C07D491/04

Abstract:
A series of substituted fused tricyclic imidazo pyrazine derivatives and analoges thereof, represented by formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Public/Granted literature
- US20180298006A1 Fused Tricyclic Imidazo Pyrazines as Modulators of TNF Activity Public/Granted day:2018-10-18
Information query